| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,450 | 6,800 | 08:27 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 22,200 | 30 | |||
| 15,000 | 15 | |||
| 11,000 | 500 | |||
| 6,800 | 1.564 | |||
| 6,350 | 500 | |||
| 6,250 | 715 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 715 | 5,950 | |||
| 1.564 | 5,450 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 4.040 | 0,832 | 3.363 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | - | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 22.07. | 4basebio Plc - Grant of Options & Director/PDMR Dealing | 366 | PR Newswire | 4basebio Plc - Grant of Options & Director/PDMR Dealing
PR Newswire
LONDON, United Kingdom, July 22
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 08.07. | 4basebio Plc - Director Appointment | 581 | PR Newswire | 4basebio Plc - Director Appointment
PR Newswire
LONDON, United Kingdom, July 08
4basebio PLC
("4basebio" or the "Company")
... ► Artikel lesen | |
| 30.06. | 4basebio Plc - Result of AGM & Issue of Options | 416 | PR Newswire | 4basebio Plc - Result of AGM & Issue of Options
PR Newswire
LONDON, United Kingdom, June 30
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 16.06. | 4basebio Plc - Notice of Investor Presentation | 406 | PR Newswire | 4basebio Plc - Notice of Investor Presentation
PR Newswire
LONDON, United Kingdom, June 16
4basebio... ► Artikel lesen | |
| 15.06. | IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board | 1 | Alliance News |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 07:58 | Novo Nordisk gerät unter Druck, Eli Lilly zieht davon - warum Big Pharma dringend neue Wachstumstreiber braucht | Small- & Micro Cap Investment | ||
| Di | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | GlobeNewswire (Europe) | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen | |
| Di | MacroGenics, Inc.: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program | GlobeNewswire (Europe) | ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment... ► Artikel lesen | |
| Di | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | GlobeNewswire (Europe) | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| Di | Belite Bio, Inc: Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 | GlobeNewswire (Europe) | Prescription Drug User Fee Act target action date is February 12, 2027If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 SAN DIEGO, Aug. 11, 2026 (GLOBE... ► Artikel lesen |